Feb 13, 2018
Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers
O. M.T. Pearce, R. M. Delaine-Smith, E. Maniati, S. Nichols, J. Wang, S. Böhm, V. Rajeeve, D. Ullah, P. Chakravarty, R. R. Jones, A. Montfort, T. Dowe, J. Gribben, J. L. Jones, H. M. Kocher, J. S. Serody, B. G. Vincent, J. Connelly, J. D. Brenton, C. Chelala, P. R. Cutillas, M. Lockley, C. Bessant, M. M. Knight, F. R. Balkwill , Cancer Discovery , DOI: 10.1158/2159-8290.CD-17-0284
We have profiled, for the first time, an evolving human metastatic microenvironment by measuring gene expression, matrisome proteomics, cytokine and chemokine levels, cellularity, extracellular matrix organization, and biomechanical properties, all on the same sample. Using biopsies of high-grade serous ovarian cancer metastases that ranged from minimal to extensive disease, we...
Jan 3, 2018
Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
C. A. Martin, C. Cullinane, L. Kirby, S. Abuhammad, E. J. Lelliott, K. Waldeck, R. J. Young, N. Brajanovski, D. P. Cameron, R. Walker, E. Sanij, G. Poortinga, R. D. Hannan, R. B. Pearson, R. J. Hicks, G. A. McArthur, K. E. Sheppard , International Journal of Cancer , DOI: 10.1002/ijc.31220
Increased CDK4 activity occurs in the majority of melanomas and CDK4/6 inhibitors in combination with BRAF and MEK inhibitors are currently in clinical trials for the treatment of melanoma. We hypothesize that the timing of the addition of CDK4/6 inhibitors to the current BRAF and MEK inhibitor regime will impact...
Dec 28, 2017
Intraepithelial CD8 (+) Lymphocytes as a Predictive Diagnostic Biomarker for the Remission of Oral Lichen Planus
A. Enomoto, E. Sato, T. Yasuda, T. Isomura, T. Nagao, D. Chikazu , Science Direct , DOI: 10.1016/j.humpath.2017.12.008
Oral lichen planus (OLP) is an autoimmune inflammatory disease of the oral mucosa whose etiology remains unknown. Moreover, the possibility of OLP being a premalignant change is under debate. Various types of immune cells infiltrate the OLP lesion and affect its clinicopathological features. However, the diversity of infiltrating immune cells...
Dec 26, 2017
CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model
L. Mayr, C. Pirker, D. Lötsch, S. Van Schoonhoven, R. Windhager, B. Englinger, W. Berger, B. Kubista , Oncotarget , DOI: 10.18632/oncotarget.23125
Background: Osteosarcoma is the most common primary malignant bone tumor with a 5 year survival rate of up to 70%. However, patients with metastatic disease have still a very poor prognosis. Osteosarcoma metastasis models are essential to develop novel treatment strategies for advanced disease.Methods: Based on a serial transplantation approach,...
Dec 21, 2017
Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1
M. Cifdaloz, L. Osterloh, O. Graña, E. Riveiro-Falkenbach, P. Ximénez-Embún, J. Muñoz, C. Tejedo, T. G. Calvo, P. Karras, D. Olmeda, B. Miñana, G. Gómez-López, E. Cañon, E. Eyras, H. Guo, F. Kappes, P. L. Ortiz-Romero, J. L. Rodríguez-Peralto, D. Megías, J. Valcárcel, M. S. Soengas , nature communications , DOI:10.1038/s41467-017-02353-y
Melanomas are well-known for their altered mRNA expression profiles. Yet, the specific contribution of mRNA binding proteins (mRBPs) to melanoma development remains unclear. Here we identify a cluster of melanoma-enriched genes under the control of CUGBP Elav-like family member 1 (CELF1). CELF1 was discovered with a distinct prognostic value in...